Evidence map›Paper›PMID 42740438›Full record

Trial reportGut and liver2026

Fourteen-Day Amoxicillin- or Tetracycline-Containing Bismuth Quadruple Therapy versus 14-Day Metronidazole-Based Triple Therapy as the Treatment for Clarithromycin-Resistant

Myeongseok Koh, Cheol Woong Choi, Dae Gon Ryu, Seung Jung Yu, Sung Eun Kim, Kyoungwon Jung, Bong Eun Lee, Moon Won Lee, Dong Chan Joo, Jin Lee and 2 more

Abstract readMulticenter StudyRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Myeongseok KohDepartment of Internal Medicine, Dong-A University Hospital, Busan, Korea.ORCID https://orcid.org/0000-0002-2000-1196
Cheol Woong ChoiDepartment of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.ORCID https://orcid.org/0000-0001-8867-3039
Dae Gon RyuDepartment of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.ORCID https://orcid.org/0000-0001-6670-4420
Seung Jung YuDepartment of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0003-3725-3901
Sung Eun KimDepartment of Internal Medicine, Kosin University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0002-1835-4830
Kyoungwon JungDepartment of Internal Medicine, Kosin University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0002-5324-7803
Bong Eun LeeDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.ORCID https://orcid.org/0000-0003-2734-2134
Moon Won LeeDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.ORCID https://orcid.org/0000-0002-8411-6398
Dong Chan JooDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.ORCID https://orcid.org/0000-0001-8734-4938
Jin LeeDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0003-2404-385X
Ra Ri ChaDepartment of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea.ORCID https://orcid.org/0000-0001-6024-9201
Sam Ryong JeeDepartment of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0002-7928-1153

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Combination therapy comprising a proton pump inhibitor (PPI), amoxicillin, and metronidazole (PAM) is used to treat clarithromycin-resistant Methods: This prospective multicenter study enrolled patients with clarithromycin-resistant Results: In the intention-to-treat (ITT) analysis, the eradication rate was significantly lower in the PAM group (68.2%) than in the PAM-B group (84.8%, p=0.024), whereas the difference from the PBMT group (81.8%) was not significant (p=0.070). The rate remained lowest in the PAM group (75.4%) in the per-protocol (PP) analysis (PAM-B, 96.5%, p=0.001; PBMT, 94.6%, p=0.004). Eradication rates were comparable between the PAM-B and PBMT groups in both the ITT (p=0.640) and PP analyses (p=0.633). Nausea and vomiting were significantly less frequent in the PAM-B group than in the PBMT group (6.8% vs 25.0%; p=0.007). Severe adverse events were rare, and all symptoms resolved after treatment discontinuation. Conclusions: PAM-B yielded eradication rates higher than those of PAM and comparable to those of PBMT, with no significant increase in the incidence of adverse events, suggesting the potential of PAM-B as a first-line treatment for clarithromycin-resistant

Indexed as

AmoxicillinAnti-Bacterial AgentsBismuthHelicobacter InfectionsHelicobacter pyloriMetronidazoleTetracyclineAdultAgedClarithromycinDrug Administration ScheduleDrug Resistance, BacterialDrug Therapy, CombinationFemaleHumansMaleAmoxicillinAnti-Bacterial AgentsBismuthClarithromycinMetronidazoleProton Pump InhibitorsTetracyclineAntibiotic resistanceBismuthClarithromycinEradication

Identifiers

PMID42740438
PMCPMC13575833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.